Meeting
2017 Palliative and Supportive Care in Oncology Symposium
Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen.
Authors
Eric Roeland
University of California San Diego Moores Cancer Center, La Jolla, CA
Eric Roeland, Gary Binder, Joseph Ma, Corinna Lanzarotti, Li Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Integration and Delivery of Palliative and Supportive Care,Communication and Shared Decision Making,Symptom Biology, Assessment, and Management,Models of Care
Sub Track
Integration and Delivery of Palliative and Supportive Care
Citation
J Clin Oncol 35, 2017 (suppl 31S; abstract 120)
DOI
10.1200/JCO.2017.35.31_suppl.120
Abstract #
120
Poster Bd #
D6
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).
First Author: Li Zhang
Poster
2023 ASCO Annual Meeting
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.
First Author: Venkatraman Radhakrishnan
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2021 ASCO Annual Meeting
Assessing duration of breakthrough chemotherapy-induced nausea and vomiting (CINV): A pooled study analysis of NEPA versus aprepitant.
First Author: Rudolph M. Navari